Gilead Sciences (GILD) 109.72 $GILD
Final Glance: Biotechnology companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Midday Glance: Biotechnology companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Early Glance: Biotechnology companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties
PR Newswire - Tue Nov 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), GT Advanced Technologies (OTCMKTS:GTATQ), GoPro (NASDAQ:GPRO), Plug Power (NASDAQ
LUG), Gilead Sciences (NASDAQ:GILD), and American Realty Capital Properties (NASDAQ:ARCP).
GPRO: 82.27 (-2.05), GILD: 109.72 (-0.26), PLUG: 5.35 (+0.21), ARCP: 8.15 (+0.30), BABA: 106.07 (+4.27)
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert
Marketwired - Tue Nov 04, 5:16AM CST
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It has become difficult, if not nearly impossible, for many of America's politicians to find common ground at any level. The outlier in this case appears to be the courting and landing of new life science industry facilities. In North America alone, there are currently 200 reported new-facility builds on the books, representing a total investment value of $15.4 billion.
GILD: 109.72 (-0.26), BAX: 68.45 (-1.23)
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
Gilead Sciences claims seven top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
GILD: 109.72 (-0.26)
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks
at The Street - Tue Nov 04, 4:00AM CST
The trading panel discussed financial, chipmaker and pharmaceutical companies.
YHOO: 47.08 (+0.74), GPRO: 82.27 (-2.05), GILD: 109.72 (-0.26), XOP: 57.12 (-2.46), UTX: 106.88 (+0.58), SUNE: 19.65 (-0.36), FFIV: 125.64 (+1.27), MCD: 94.47 (+0.86), SLV: 15.36 (-0.12), TLT: 119.33 (+0.37), NVDA: 20.13 (+0.26), BABA: 106.07 (+4.27)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 83.46 (-1.12), ISIS: 45.60 (-0.33), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26), SSYS: 121.25 (-1.32), HP: 80.69 (-3.60), REGN: 372.39 (-22.87), CELG: 105.75 (-1.66)
Research and Markets: Gilead Sciences Clinical Development Profile 2014
Business Wire - Mon Nov 03, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/t4gpb2/gilead_sciences) has announced the addition of the "Gilead Sciences Clinical Development Profile" report to their offering.
GILD: 109.72 (-0.26)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), GILD: 109.72 (-0.26), ABBV: 62.66 (-0.59)
Gilead Sciences Clinical Development Profile 2014
M2 - Mon Nov 03, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/9npndw/gilead_sciences) has announced the addition of the "Gilead Sciences Clinical Development Profile" report to their offering. With a market capitalization greater than $100B, Gilead is fast becoming one of the most influential pharmaceutical companies in the world. The report provides a thorough analysis of Gilead Sciences' R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Gilead's key products. HOW YOU CAN USE THIS REPORT: - Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar/ competing products. - Service Providers: Better prepare your business development activities focused on Gilead. Understand their strategic direction, current and potential clinical development pipeline, and historic trial metrics. Key Topics Covered: 1. Methodology and sources 2. Background and strategy 3. R&D pipeline overview 4. Clinical trial activity 5. Patents 6. FDA submissions 7. Key product profiles 7. Summary For more information visit http://www.researchandmarkets.com/research/9n...d_sciences
GILD: 109.72 (-0.26)
Surging Earnings Estimates Signal Good News for Gilead (GILD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:40AM CST
Gilead has been witnessing a positive trend in its current year earnings estimate and possess a favorable Zacks Rank #2 (Buy)
GILD: 109.72 (-0.26)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
2 More Gilead Sciences, Inc. Blockbusters You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 03, 6:40AM CST
Source: Gilead Sciences. Gilead Sciences hepatitis C drugs may be capturing all the attention, but its Gilead's HIV drug franchise that's been responsible for the company's long-standing success. Gilead is racking up billions in global revenue...
JNJ: 108.62 (+1.16), GILD: 109.72 (-0.26)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 74.65 (+1.07), AAP: 148.44 (+0.68), AKRX: 42.64 (-1.18), ILMN: 191.41 (-2.92), NXPI: 69.67 (+0.42), CDW: 31.04 (-0.02), CELG: 105.75 (-1.66), BIDU: 241.96 (+5.42), GILD: 109.72 (-0.26), JAZZ: 168.48 (-1.85), FLT: 148.53 (-1.70), FL: 53.63 (-2.54), AAPL: 108.60 (-0.80), AVGO: 85.36 (-0.98)
Fundamentals, Technicals Still Intact At Gilead Sciences
at Investor's Business Daily - Fri Oct 31, 4:36PM CDT
Some analysts called Gilead Sciences' third-quarter earnings report on Oct. 28 "sloppy." But make no mistake: It's still a company in growth mode. And its weekly chart doesn't look bad either. Gilead's (GILD) earnings per share slightly missed...
GILD: 109.72 (-0.26)
Final Glance: Biotechnology companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Midday Glance: Biotechnology companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Early Glance: Biotechnology companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties
PR Newswire - Tue Nov 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), GT Advanced Technologies (OTCMKTS:GTATQ), GoPro (NASDAQ:GPRO), Plug Power (NASDAQ
LUG), Gilead Sciences (NASDAQ:GILD), and American Realty Capital Properties (NASDAQ:ARCP). GPRO: 82.27 (-2.05), GILD: 109.72 (-0.26), PLUG: 5.35 (+0.21), ARCP: 8.15 (+0.30), BABA: 106.07 (+4.27)
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert
Marketwired - Tue Nov 04, 5:16AM CST
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It has become difficult, if not nearly impossible, for many of America's politicians to find common ground at any level. The outlier in this case appears to be the courting and landing of new life science industry facilities. In North America alone, there are currently 200 reported new-facility builds on the books, representing a total investment value of $15.4 billion.
GILD: 109.72 (-0.26), BAX: 68.45 (-1.23)
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
Gilead Sciences claims seven top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
GILD: 109.72 (-0.26)
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks
at The Street - Tue Nov 04, 4:00AM CST
The trading panel discussed financial, chipmaker and pharmaceutical companies.
YHOO: 47.08 (+0.74), GPRO: 82.27 (-2.05), GILD: 109.72 (-0.26), XOP: 57.12 (-2.46), UTX: 106.88 (+0.58), SUNE: 19.65 (-0.36), FFIV: 125.64 (+1.27), MCD: 94.47 (+0.86), SLV: 15.36 (-0.12), TLT: 119.33 (+0.37), NVDA: 20.13 (+0.26), BABA: 106.07 (+4.27)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 83.46 (-1.12), ISIS: 45.60 (-0.33), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26), SSYS: 121.25 (-1.32), HP: 80.69 (-3.60), REGN: 372.39 (-22.87), CELG: 105.75 (-1.66)
Research and Markets: Gilead Sciences Clinical Development Profile 2014
Business Wire - Mon Nov 03, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/t4gpb2/gilead_sciences) has announced the addition of the "Gilead Sciences Clinical Development Profile" report to their offering.
GILD: 109.72 (-0.26)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), GILD: 109.72 (-0.26), ABBV: 62.66 (-0.59)
Gilead Sciences Clinical Development Profile 2014
M2 - Mon Nov 03, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/9npndw/gilead_sciences) has announced the addition of the "Gilead Sciences Clinical Development Profile" report to their offering. With a market capitalization greater than $100B, Gilead is fast becoming one of the most influential pharmaceutical companies in the world. The report provides a thorough analysis of Gilead Sciences' R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Gilead's key products. HOW YOU CAN USE THIS REPORT: - Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar/ competing products. - Service Providers: Better prepare your business development activities focused on Gilead. Understand their strategic direction, current and potential clinical development pipeline, and historic trial metrics. Key Topics Covered: 1. Methodology and sources 2. Background and strategy 3. R&D pipeline overview 4. Clinical trial activity 5. Patents 6. FDA submissions 7. Key product profiles 7. Summary For more information visit http://www.researchandmarkets.com/research/9n...d_sciences
GILD: 109.72 (-0.26)
Surging Earnings Estimates Signal Good News for Gilead (GILD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:40AM CST
Gilead has been witnessing a positive trend in its current year earnings estimate and possess a favorable Zacks Rank #2 (Buy)
GILD: 109.72 (-0.26)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
2 More Gilead Sciences, Inc. Blockbusters You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 03, 6:40AM CST
Source: Gilead Sciences. Gilead Sciences hepatitis C drugs may be capturing all the attention, but its Gilead's HIV drug franchise that's been responsible for the company's long-standing success. Gilead is racking up billions in global revenue...
JNJ: 108.62 (+1.16), GILD: 109.72 (-0.26)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 74.65 (+1.07), AAP: 148.44 (+0.68), AKRX: 42.64 (-1.18), ILMN: 191.41 (-2.92), NXPI: 69.67 (+0.42), CDW: 31.04 (-0.02), CELG: 105.75 (-1.66), BIDU: 241.96 (+5.42), GILD: 109.72 (-0.26), JAZZ: 168.48 (-1.85), FLT: 148.53 (-1.70), FL: 53.63 (-2.54), AAPL: 108.60 (-0.80), AVGO: 85.36 (-0.98)
Fundamentals, Technicals Still Intact At Gilead Sciences
at Investor's Business Daily - Fri Oct 31, 4:36PM CDT
Some analysts called Gilead Sciences' third-quarter earnings report on Oct. 28 "sloppy." But make no mistake: It's still a company in growth mode. And its weekly chart doesn't look bad either. Gilead's (GILD) earnings per share slightly missed...
GILD: 109.72 (-0.26)
